News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
New data forecast more oral PDE4 inhibitors for psoriasis
- Author:
- Ted Bosworth
The phase 2b data suggest that the drug, called orismilast, “is a potential new addition to the psoriasis armamentarium,” said Lars E. French, MD...
News
New JAK inhibitor study data confirm benefit in alopecia areata
- Author:
- Ted Bosworth
Deuruxolitinib (CTP-543), an inhibitor of the JAK1 and JAK2 enzymes, has the potential to become the second JAK inhibitor available for the...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Kapadia_Samir_OH_CRT2023_web.jpg)
LAA closure device shown safe in groups omitted in trials
- Author:
- Ted Bosworth
New independent studies support safety of left atrial appendage closure devices in broad array of patient types.
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Novel therapy shows promise for treating skin-predominant dermatomyositis
- Author:
- Ted Bosworth
The study drug “is a potent, selective humanized IgG1-neutralizing antibody directed at IFN-beta,” said Dr. Aaron Mangold, the principal...
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Studies validate IL-17 as hidradenitis suppurativa drug target
- Author:
- Ted Bosworth
This clearly validates this target for the control of HS," reported lead investigator Alexa B. Kimball, MD, MPH.
News
JAK inhibitor safety warnings drawn from rheumatologic data may be misleading in dermatology
- Author:
- Ted Bosworth
The recently approved deucravacitinib is the only JAK inhibitor that has so far been exempt from these warnings.
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Wearable fluid sensor lowers risk of HF rehospitalizations: BMAD
- Author:
- Ted Bosworth
By detecting elevated thoracic fluid levels, a wearable device improves management and outcomes of heart failure.
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
FREEDOM COVID: Full-dose anticoagulation cut mortality but missed primary endpoint
- Author:
- Ted Bosworth
In an in-hospital anticoagulation trial, the primary COVID endpoint was missed but a survival benefit is observed.
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Fixed-dose combo pill for PAH promises accelerated benefit: A DUE
- Author:
- Ted Bosworth
For pulmonary arterial hypertension, a fixed-dose combination of macitentan and tadalafil is safe and effective.
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
In early days, bioabsorbable stent rivals nonabsorbable devices
- Author:
- Ted Bosworth
Late lumen loss with a new bioabsorbable drug-eluting stent is on par with nonabsorbable devices in early data.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Bhatt_Deepak_MA2_web.jpg)
Long-term BP reductions with renal denervation not race specific
- Author:
- Ted Bosworth
Long-term blood pressure reductions in the Black patient cohort of the SYMPLICITY renal denervation trial challenge early results.
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Causal AI quantifies CV risk, providing patient-specific goals
- Author:
- Ted Bosworth
Causal artificial intelligence is showing how specific risk factors can be overcome to avoid cardiovascular events.
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
When intravascular imaging guides complex PCI, MACE risk is lowered
- Author:
- Ted Bosworth
In stent placement for complex coronary lesions, intravascular imaging reduces events relative to angiography.
News
![](https://www.qa.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
Transcatheter tricuspid valve repair effective and safe for regurgitation
- Author:
- Ted Bosworth
In a randomized pivotal trial, a percutaneous repair of tricuspid valve regurgitation was effective and safe.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Jakubov_Steven_OH_web.jpg)
At 5 years, TAVI valves perform better than surgical ones
- Author:
- Ted Bosworth
TAVR valves deteriorate less than surgical valves at 5 years in patients treated for severe aortic stenosis.